Autopsy report · NCT00997243

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

“Drug no longer being supplied by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 7 participants enrolled.
• Results were posted on the registry 2 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Alison Walker

Sponsor type

University, hospital or other

Conditions

Leukemia; Myelodysplastic Syndromes

Interventions

lintuzumab; 5-azacytidine

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer
  “Drug sponsor stopped drug manufacture due to toxicity issues from other studies” (77% match in meaning)
• GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
  “Lost sponsorship for study drug” (77% match in meaning)
• Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
  “Sponsor stops to provide the study drug.” (74% match in meaning)
• A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
  “Sponsor's decision for the Drug Development.” (74% match in meaning)
• Phase I Study of CS-7017 and Bexarotene
  “Drug no longer available” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.